Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Avid Radiopharmaceuticals

Request full access

Molecular imaging agents for detecting and monitoring chronic human diseases

Philadelphia, United StatesFounded 2004Biotech & Life Sciences

About Avid Radiopharmaceuticals

Avid Radiopharmaceuticals operates as a key player in the field of molecular imaging, focusing on the development of agents to detect and monitor chronic diseases. The company was established in late 2004 by Dr. Daniel M. Skovronsky, who leveraged his background as the former Scientific Director at the University of Pennsylvania's Center for Neurodegenerative Disease Research to address a critical gap in medical diagnostics. Dr. Skovronsky, who holds an M.D. and Ph.D. from the University of Pennsylvania, founded the company to create a diagnostic tool for Alzheimer's disease that could be used on living patients, moving beyond the traditional post-mortem diagnosis.

A significant milestone in the company's history was its acquisition by Eli Lilly and Company in December 2010. The deal involved an upfront payment of $300 million, with an additional potential of $500 million contingent on regulatory and commercial milestones. Following the acquisition, Avid Radiopharmaceuticals became a wholly-owned subsidiary of Lilly, continuing its operations from Philadelphia.

The company's core business revolves around the development and commercialization of radiopharmaceuticals used with Positron Emission Tomography (PET) scans. Its flagship product is Amyvid™ (Florbetapir F 18), a radioactive diagnostic agent designed to estimate the density of beta-amyloid plaques in the brain. These plaques are a defining pathology of Alzheimer's disease. Amyvid works by binding to these amyloid plaques, which can then be visualized in PET scan images. A negative scan indicates few to no plaques, reducing the likelihood that cognitive impairment is due to Alzheimer's. Conversely, a positive scan shows a moderate to frequent amount of plaque, which, while characteristic of Alzheimer's, can also be present in other neurological conditions or in cognitively normal older adults. Therefore, the product serves as an adjunct diagnostic tool for physicians evaluating patients with cognitive decline.

Amyvid received FDA approval in April 2012 and subsequently gained marketing authorization in the European Union in early 2013. The company also has a broader diagnostics development platform exploring agents for other conditions, including Parkinson's disease and diabetes. Its business model appears to be centered on the revenue generated from the sale of its imaging agents to healthcare providers and its use in clinical trials for Alzheimer's treatments being developed by other pharmaceutical firms. Avid provides its products and support for major academic clinical trials, such as the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Source: Dealroom company data

At a glance

Status
Acquired
Employees
127
Open positions
None listed
Dealroom signal
59.4/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Personal Health, Diabetes, Biotechnology, Oncology, Health Diagnostics, Hard Tech, Radiopharmaceuticals, DT and LS, science-based
Technology
Big Data
Client focus
B2B
Links
Website

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITIONOther financing Nov 2010 $800M $800M Undisclosed —
SERIES DOther financing May 2009 $35M $138M Lilly Ventures · BioAdvance · Osage University Partners · AllianceBernstein —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Avid Radiopharmaceuticals website traffic

Latest recorded traffic for Avid Radiopharmaceuticals is 240 monthly website visits, up 9.1% over the last three months. Avid Radiopharmaceuticals's team grew 0% over the past year.

Latest monthly visits240 3-month web change+9.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Avid Radiopharmaceuticals in the Philadelphia ecosystem

Live from Dealroom

The Avid Radiopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • BioAdvance

Series A1 investor entered at this stage

  • Pfizer Ventures

Series B and later6 investors entered at this stage

  • AllianceBernstein
  • Safeguard Scientifics
  • RK Ventures Group
  • Lilly Ventures
  • Alta Partners
  • Osage University Partners
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Philadelphia HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Avid Radiopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Avid Radiopharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.